SAN DIEGO--(BUSINESS WIRE)--Accelrys, Inc. (NASDAQ:ACCL) a leader in Computer Aided Nanodesign™ (CAN), announced the release of QMERA, the latest software solution developed by the Accelrys Nanotechnology Consortium. QMERA is a multi-scale method that enables users to include quantum mechanical and molecular mechanic methods (QMMM) simultaneously through a hybrid simulation approach. QMERA will be commercially available to members of the Nanotechnology Consortium as part of Materials Studio 4.2, expected to be released in July 2007.
The Nanotechnology Consortium, launched in 2004, develops and commercializes innovative science that helps researchers investigate complex models of nanostructures and devices. The success of the Nanotechnology Consortium is not only measured by its 29 members, but by the amount of new software solutions it has developed to meet customers’ needs. In addition to QMERA, Nanotechnology Consortium development efforts have resulted in software included in Materials Studio 3.2, 4.0 and 4.1. The software includes ONETEP, a true linear scaling quantum mechanics program and GULP, an advanced force field package for calculating a wide range of materials properties.
Accelrys has also added new members to the Nanotechnology Consortium. The new members include the National Nanotechnology Center (NANOTEC) in Thailand, and DENSO Corporation.
Dr. Noppawan Tanpipat, Deputy Executive Director, NANOTEC, said, “Here at NANOTEC we have recently launched a new initiative to introduce and integrate an advanced platform for nanoscale simulations into our Research Development Design and Engineering process. Computer Aided Nanodesign fits well within our model with the continuum span from discovery to development and with real world applications focused at the nanoscale.”
Julian Gale, Professor at Curtin University in Perth, Western Australia, and Consortium Advisor and author of GULP, said, “The Nanotechnology Consortium is a great example of global collaboration successfully driving forward the computational tools needed for nanomaterials research. I am very pleased about the growth of the Membership, which clearly demonstrates the strength of and need for this level of nanotechnology research.”
The Nanotechnology Consortium contributes to Accelrys’ ability to provide Scientific Business Intelligence solutions across the full spectrum of a company’s R&D organization by enhancing the existing portfolio of multi-scale tools to connect adjoining technologies.
Following on the success of Phase I of the Nanotechnology Consortium, Accelrys is planning to launch Phase II later this year. For more information visit http://www.accelrys.com/materials/nano/nano_consortium/
About Accelrys, Inc.
Accelrys develops and commercializes Scientific Business Intelligence software for the integration, mining, analysis, modeling and simulation, management and interactive reporting of scientific data. Our solutions are used by biologists, chemists, materials scientists, and information technology professionals for product design as well as drug discovery and development. Our technology and services are designed to meet the needs of today’s leading research and development organizations including leading commercial, government and academic organizations. Many of the largest pharmaceutical, biotechnology, chemical, and petroleum companies worldwide use our solutions. Accelrys is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/
This press release contains forward-looking statements. Such statements, including statements relating to the Company’s products, including the products’ features and potential demand therefore, are subject to risks and uncertainties including, but not limited to, the risks that the products will not be timely or successfully completed, developed or achieve market acceptance, demand relating to these products, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.